IMVT - NASDAQ
Immunovant, Inc.
$31.15
+1.2%Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
At a Glance
Live Snapshotimvt
Total Liabilities
Last Annual Value
104.42M
3-Year CAGR
34%
5-Year CAGR
38%
10-Year CAGR
52%
Immunovant, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Immunovant, Inc. NASDAQ:IMVT | 104.42M | 34.1% | 37.8% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 113.72M | 69.9% | 45.0% | 48.9% | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 163.15M | -3.4% | 2.2% | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 76.67M | 56.3% | 54.3% | 28.0% | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 143.41M | 14.2% | 49.7% | 22.5% | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 1.60B | 9.7% | 21.8% | 37.5% | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 214.83M | 42.8% | 30.2% | -32.5% | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 336.81M | 2.0% | 16.2% | 22.9% | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 85.85M | 13.5% | 49.8% | N/A | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 75.77M | 19.0% | 23.4% | N/A | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 59.77M | 48.4% | 7.3% | N/A |
Immunovant, Inc. Fair Value Envelope
Related Guides
Continue your IMVT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.